New and old adjuvants in allergen‐specific immunotherapy: With a focus on nanoparticles

Feng, Zhongtao; Yi, Xin; Hajavi, Jafar

doi:10.1002/jcp.29941

Cited by 13 publications

(10 citation statements)

References 146 publications

(231 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although AIT is an effective treatment for AR, it is not without limitations including cumbersome‐up‐dosing regimens, systemic reactions, and variable efficacy 1668 . Adjuvants are chemicals and proteins that may enhance the safety, convenience, and immunological effects of AIT 2468–2474 . Effective AIT attenuates pro‐inflammatory Th2 responses in favor of tolerogenic Treg responses.…”

Section: Managementmentioning

confidence: 99%

“…Separately, an oral microencapsulated form of Timothy grass allergen was used to treat patients with AR over a period of 10 weeks; patients in the active treatment group experienced decreased symptom scores compared to placebo 2526 . Limited human trial data suggest that encapsulated allergens may induce immune responses but further understanding of their role in AIT is needed 2474 …”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

157

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

157

View full text Add to dashboard Cite

show abstract

“…In humans, CYT003-QbG10 VLPs (TLR9 agonists arranged into VLPs) improve the AR quality of life, asthma symptoms, and lung function [ 126 , 127 ]. Extensive reviews on the role of adjuvants in AIT have already been published [ 128 , 129 ]…”

Section: Adjuvantsmentioning

confidence: 99%

Allergen Immunotherapy: Current and Future Trends

Pavón-Romero

Parra-Vargas

Ramírez-Jiménez

et al. 2022

Cells

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) is the sole disease-modifying treatment for allergic rhinitis; it prevents rhinitis from progressing to asthma and lowers medication use. AIT against mites, insect venom, and certain kinds of pollen is effective. The mechanism of action of AIT is based on inducing immunological tolerance characterized by increased IL-10, TGF-β, and IgG4 levels and Treg cell counts. However, AIT requires prolonged schemes of administration and is sometimes associated with adverse reactions. Over the last decade, novel forms of AIT have been developed, focused on better allergen identification, structural modifications to preserve epitopes for B or T cells, post-traductional alteration through chemical processes, and the addition of adjuvants. These modified allergens induce clinical-immunological effects similar to those mentioned above, increasing the tolerance to other related allergens but with fewer side effects. Clinical studies have shown that molecular AIT is efficient in treating grass and birch allergies. This article reviews the possibility of a new AIT to improve the treatment of allergic illness.

show abstract

“…), thereby expanding the boundaries of immunotherapy. 20,21 Therefore, it would be a wise and win−win strategy to engineer a nanobiotechnology platform to achieve high-precision LTD for systemic cancer immunotherapy. Based on this approach, except for the direct killing effect of LTD, vaccinelike effects maintaining high immune activity can be in situ-generated without sophisticated procedures.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, the combination of nanobiotechnology and cancer immunotherapy can also overcome the challenges associated with traditional immunotherapy (e.g., off-target toxicities, short therapeutic duration, poor immunogenicity, etc. ), thereby expanding the boundaries of immunotherapy. , Therefore, it would be a wise and win–win strategy to engineer a nanobiotechnology platform to achieve high-precision LTD for systemic cancer immunotherapy. Based on this approach, except for the direct killing effect of LTD, vaccinelike effects maintaining high immune activity can be in situ -generated without sophisticated procedures. , Meanwhile, nanoparticles (NPs) with high surface areas could be employed as carriers of adjuvants or tumor antigens to protect them from degradation and premature release. − Furthermore, it has been established that some types of NPs with good affinity with tumor antigens could effectively capture tumor-derived protein antigens (TDPAs) generated from LTD and enhance the efficiency of its delivery at the same time, further improving the treatment response to immunotherapy …”

Section: Introductionmentioning

confidence: 99%

Local Destruction of Tumors for Systemic Immunoresponse: Engineering Antigen-Capturing Nanoparticles as Stimulus-Responsive Immunoadjuvants

Guo

Zheng

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Immunotherapy has established a new paradigm for cancer treatment and made many breakthroughs in clinical practice. However, the rarity of immune response suggests that additional intervention is necessary. In recent years, it has been reported that local tumor destruction (LTD) can cause cancer cell death and induce an immunologic response. Thus, the combination of immunotherapy and LTD methods will be a promising approach to improve immune efficiency for cancer treatment. Herein, a nanobiotechnology platform to achieve high-precision LTD for systemic cancer immunotherapy has been successfully constructed. Possessing radio-sensitizing and photothermal properties, the engineered immunoadjuvant-loaded nanoplatform, which could precisely induce radiotherapy (RT)/photothermal therapy (PTT) to eliminate local tumor and meanwhile lead to the release of tumor-derived protein antigens (TDPAs), has been facilely fabricated by commercialized SPG membrane emulsification technology. Further on, the TDPAs could be captured and form personal nanovaccines in situ to serve as both reservoirs of antigen and carriers of immunoadjuvant, which can effectively improve the immune response. The investigations suggest that the combination of RT/PTT and improved immunotherapy using adjuvant-encapsulated antigen-capturing nanoparticles holds tremendous promise in cancer treatments.

show abstract

New and old adjuvants in allergen‐specific immunotherapy: With a focus on nanoparticles

Cited by 13 publications

References 146 publications

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Allergen Immunotherapy: Current and Future Trends

Local Destruction of Tumors for Systemic Immunoresponse: Engineering Antigen-Capturing Nanoparticles as Stimulus-Responsive Immunoadjuvants

Contact Info

Product

Resources

About